440 related articles for article (PubMed ID: 9685056)
1. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Kumazawa E; Jimbo T; Ochi Y; Tohgo A
Cancer Chemother Pharmacol; 1998; 42(3):210-20. PubMed ID: 9685056
[TBL] [Abstract][Full Text] [Related]
2. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo.
Mitsui I; Kumazawa E; Hirota Y; Aonuma M; Sugimori M; Ohsuki S; Uoto K; Ejima A; Terasawa H; Sato K
Jpn J Cancer Res; 1995 Aug; 86(8):776-82. PubMed ID: 7559102
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
4. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
5. Induction of breast cancer resistance protein by the camptothecin derivative DX-8951f is associated with minor reduction of antitumour activity.
van Hattum AH; Hoogsteen IJ; Schlüper HM; Maliepaard M; Scheffer GL; Scheper RJ; Kohlhagen G; Pommier Y; Pinedo HM; Boven E
Br J Cancer; 2002 Sep; 87(6):665-72. PubMed ID: 12237778
[TBL] [Abstract][Full Text] [Related]
6. The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.
van Hattum AH; Pinedo HM; Schlüper HM; Erkelens CA; Tohgo A; Boven E
Biochem Pharmacol; 2002 Oct; 64(8):1267-77. PubMed ID: 12234607
[TBL] [Abstract][Full Text] [Related]
7. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Nomoto T; Nishio K; Ishida T; Mori M; Saijo N
Jpn J Cancer Res; 1998 Nov; 89(11):1179-86. PubMed ID: 9914787
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF; Kudelka AP; Hu W; Vincent M; Kavanagh JJ; Loyer E; Bastien L; Duggal A; De Jager R
Cancer Chemother Pharmacol; 2004 Jan; 53(1):1-7. PubMed ID: 14586557
[TBL] [Abstract][Full Text] [Related]
10. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Vey N; Giles FJ; Kantarjian H; Smith TL; Beran M; Jeha S
Clin Cancer Res; 2000 Feb; 6(2):731-6. PubMed ID: 10690560
[TBL] [Abstract][Full Text] [Related]
11. Antitumour activity of DX-8951f: a new camptothecin derivative.
Kumazawa E; Tohgo A
Expert Opin Investig Drugs; 1998 Apr; 7(4):625-32. PubMed ID: 15991999
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
13. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies.
Rowinsky EK; Johnson TR; Geyer CE; Hammond LA; Eckhardt SG; Drengler R; Smetzer L; Coyle J; Rizzo J; Schwartz G; Tolcher A; Von Hoff DD; De Jager RL
J Clin Oncol; 2000 Sep; 18(17):3151-63. PubMed ID: 10963644
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
[TBL] [Abstract][Full Text] [Related]
15. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer.
Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E
Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
Sun FX; Tohgo A; Bouvet M; Yagi S; Nassirpour R; Moossa AR; Hoffman RM
Cancer Res; 2003 Jan; 63(1):80-5. PubMed ID: 12517781
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.
Boige V; Raymond E; Faivre S; Gatineau M; Meely K; Mekhaldi S; Pautier P; Ducreux M; Rixe O; Armand JP
J Clin Oncol; 2000 Dec; 18(23):3986-92. PubMed ID: 11099328
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Nakajima TE; Yanagihara K; Takigahira M; Yasunaga M; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Mihara K; Ochiya T; Matsumura Y
Cancer Res; 2008 Nov; 68(22):9318-22. PubMed ID: 19010905
[TBL] [Abstract][Full Text] [Related]
19. Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells.
Lawrence RA; Izbicka E; De Jager RL; Tohgo A; Clark GM; Weitman SD; Rowinsky EK; Von Hoff DD
Anticancer Drugs; 1999 Aug; 10(7):655-61. PubMed ID: 10507315
[TBL] [Abstract][Full Text] [Related]
20. The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts.
Kenmotsu H; Yasunaga M; Goto K; Nagano T; Kuroda J; Koga Y; Takahashi A; Nishiwaki Y; Matsumura Y
Cancer; 2010 Oct; 116(19):4597-604. PubMed ID: 20572031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]